Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

REACT Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy

Coordinator
Institut Pasteur, France
Runs
1 June 2024 to 30 November 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101158040

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer immunotherapies have shown impressive success in cancer treatment. However, these therapies are limited to certain type of cancers, and success rate is still low. In particular, certain types of solid tumors containing an abundant stroma, which represent a majority of epithelial derived cancer, respond very poorly to immunotherapies. In these tumors, a major challenge for the development of novel cancer immunotherapies is represented by the tumor microenvironment (TME), a highly hypoxic and immunosuppressive environment which prevents proper tumor infiltration and functioning of effector immune cells.

Recent discoveries identified tumor-activated mesenchymal stromal cells (MSCs) developing within the TME, and showed that they represent a major brake for efficient antitumor immunity in solid tumors. In this project, we will investigate the potential of a novel approach and therapeutic avenue to target specific populations of MSCs within the TME, and determine the synergistic effect with immunotherapies to improve treatment efficacy in solid tumors.

In the long term, this project aims at overcoming a major barrier in utilizing cancer immunotherapies in solid tumors.

Topics

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI